retatrutide phase 3 trial dosage produces up to 30.3% weight loss in Triple hormone receptor agonist retatrutide

GI side effects include nausea, vomiting, diarrhea and constipation, each of which compromises meeting daily caloric and nutritional needs

TAV: tejido adiposo visceral

Ania Jastreboff , MD, PHD, is an adult and pediatric endocrinologist at the Yale School of Medicine in New Haven, Connecticut

But for a country where 36% of people have lactose malabsorption, and between 80-90% of African Americans, Native Americans and Asian Americans are lactose-intolerant, how important is it to have a wider range of non-dairy products

A combined approach should be guided by a healthcare professional and monitored with appropriate labs